DE69433875D1 - Verfahren zur präparation von humanem aktiviertem protein c - Google Patents

Verfahren zur präparation von humanem aktiviertem protein c

Info

Publication number
DE69433875D1
DE69433875D1 DE69433875T DE69433875T DE69433875D1 DE 69433875 D1 DE69433875 D1 DE 69433875D1 DE 69433875 T DE69433875 T DE 69433875T DE 69433875 T DE69433875 T DE 69433875T DE 69433875 D1 DE69433875 D1 DE 69433875D1
Authority
DE
Germany
Prior art keywords
activated protein
protein
human activated
thrombin
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69433875T
Other languages
English (en)
Other versions
DE69433875T2 (de
Inventor
Yoichi Ogata
Toshinobu Nouchi
Shinji Nakahira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Teijin Ltd
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken, Teijin Ltd filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Publication of DE69433875D1 publication Critical patent/DE69433875D1/de
Application granted granted Critical
Publication of DE69433875T2 publication Critical patent/DE69433875T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds
    • Y10S530/856—Snakes; venom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE69433875T 1993-10-29 1994-10-27 Verfahren zur präparation von humanem aktiviertem protein c Expired - Lifetime DE69433875T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP29249993 1993-10-29
JP5292499A JP3043558B2 (ja) 1993-10-29 1993-10-29 ヒト活性化プロテインｃ調製物及びその製法
PCT/JP1994/001807 WO1995011966A1 (fr) 1993-10-29 1994-10-27 Preparation de proteine c humaine activee et son procede de production

Publications (2)

Publication Number Publication Date
DE69433875D1 true DE69433875D1 (de) 2004-08-05
DE69433875T2 DE69433875T2 (de) 2005-07-14

Family

ID=17782617

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69433875T Expired - Lifetime DE69433875T2 (de) 1993-10-29 1994-10-27 Verfahren zur präparation von humanem aktiviertem protein c

Country Status (11)

Country Link
US (1) US5831025A (de)
EP (1) EP0726311B1 (de)
JP (1) JP3043558B2 (de)
KR (1) KR100383063B1 (de)
CN (1) CN1123639C (de)
AT (1) ATE270327T1 (de)
AU (1) AU680563B2 (de)
CA (1) CA2175201C (de)
DE (1) DE69433875T2 (de)
ES (1) ES2224109T3 (de)
WO (1) WO1995011966A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
BR9809304B1 (pt) * 1997-04-28 2011-02-08 formulação liofilizada estável, processo para preparação da mesma, bem como forma de dosagem unitária.
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
WO2001089558A2 (en) * 2000-05-24 2001-11-29 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
WO2003007686A2 (en) * 2001-07-19 2003-01-30 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
AU2003213146A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
WO2004060395A1 (ja) * 2002-12-27 2004-07-22 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 悪性腫瘍治療における生命予後の改善剤
US20150150954A1 (en) 2012-07-04 2015-06-04 The University Of Sydney Treatment of inflammatory skin disorders
AU2014391082B2 (en) 2014-04-16 2020-04-09 Zz Biotech Llc Treatment of abnormal cutaneous scarring

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968626A (en) * 1985-08-15 1990-11-06 Board Of Reagents Of The University Of Washington DNA sequence coding for protein C
EP0380508A4 (en) * 1987-05-18 1991-04-03 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
WO1991000912A1 (en) * 1989-07-07 1991-01-24 Massachusetts Institute Of Technology Production and use of hybrid protease inhibitors
WO1991012320A1 (en) * 1990-02-09 1991-08-22 Zymogenetics, Inc. Activated protein c with truncated light chain
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
JPH0564588A (ja) * 1991-08-14 1993-03-19 Teijin Ltd 短い重鎖を有するヒトプロテインｃおよび活性化ヒトプロテインｃ

Also Published As

Publication number Publication date
JPH07115972A (ja) 1995-05-09
AU8003294A (en) 1995-05-22
KR960705921A (ko) 1996-11-08
WO1995011966A1 (fr) 1995-05-04
CN1138349A (zh) 1996-12-18
KR100383063B1 (ko) 2003-07-07
CA2175201C (en) 2007-06-12
JP3043558B2 (ja) 2000-05-22
EP0726311A1 (de) 1996-08-14
EP0726311A4 (de) 1997-06-11
US5831025A (en) 1998-11-03
CN1123639C (zh) 2003-10-08
ES2224109T3 (es) 2005-03-01
EP0726311B1 (de) 2004-06-30
CA2175201A1 (en) 1995-05-04
ATE270327T1 (de) 2004-07-15
AU680563B2 (en) 1997-07-31
DE69433875T2 (de) 2005-07-14

Similar Documents

Publication Publication Date Title
DE59409712D1 (de) Verfahren zur chromatographischen reinigung und trennung von nucleinsäuregemischen
ATE270327T1 (de) Verfahren zur präparation von humanem aktiviertem protein c
DK0495918T3 (da) Aminosyre-beta-lyaseenzyminhibitorer som deodoranter
DE68909627D1 (de) Verfahren zur Herstellung von Aktivkohle.
DE69011880D1 (de) Verfahren zur Herstellung von L-Aminosäuren durch Fermentation.
DE68916754D1 (de) Verfahren zur Herstellung von optisch aktiver 3-Hydroxybuttersäure.
ATE264913T1 (de) Protease-resistente analoge des thrombomodulin
DE3683512D1 (de) Verfahren zur optischen isomerisierung von optisch aktiver aminosaeure und verfahren zur herstellung von optisch aktiver aminosaeure.
AU692988B2 (en) Superior thrombomodulin analogs for pharmaceutical use
DE68908576D1 (de) Verfahren zur Herstellung von Aktivkohle.
DE69016879D1 (de) Verfahren zur Reinigung von N-Phosphonmethylglyzin.
ATE78239T1 (de) Verfahren zur herstellung von zeolithen.
DE59304941D1 (de) Verfahren zum Abtrennen von Aminosäuren aus wässrigen Lösungen
DE59309646D1 (de) Verfahren zur Spaltung von Proenzymen
AU2381795A (en) Methods for treating bleeding disorders
DE59007810D1 (de) Verfahren zur enzymatischen Spaltung von 2-Arylpropionsäurevinylestern.
CA2019872A1 (en) Method and kit for determining the functional activity of protein s in human plasma
ATE4453T1 (de) Aminosaeure- und peptidester von leukoindoanilinen, verfahren zu deren herstellung sowie diese verbindungen enthaltende mittel zum nachweis proteolytischer enzyme.
DE59309127D1 (de) Verfahren zur Reaktivierung von gereinigten Membranproteinen
DE68926922D1 (de) Verfahren zur Herstellung von L-alpha-Aminosäuren
DE69614733D1 (de) Verfahren zur Herstellung von optisch aktiver Aminosäure
DE59611093D1 (de) Verfahren zur Herstellung von Proteinen durch kontrollierte proteolytische spaltung von Pro-Proteinen
ES2193349T3 (es) Metodo para la produccion de rdspa alfa1.
ATE15489T1 (de) Die blutkoagulation aktivierendes produkt und verfahren zu dessen herstellung.
ATE92056T1 (de) Verfahren zur herstellung von 5-chlor-3chlorsulfonyl-2-thiophencarbonsaeureestern.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition